CN101862393B - Chinese medicinal composition for treating ureaplasma urealyticum infection and preparation method thereof - Google Patents
Chinese medicinal composition for treating ureaplasma urealyticum infection and preparation method thereof Download PDFInfo
- Publication number
- CN101862393B CN101862393B CN2010101695118A CN201010169511A CN101862393B CN 101862393 B CN101862393 B CN 101862393B CN 2010101695118 A CN2010101695118 A CN 2010101695118A CN 201010169511 A CN201010169511 A CN 201010169511A CN 101862393 B CN101862393 B CN 101862393B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- chinese medicinal
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating ureaplasma urealyticum infection and a preparation method thereof. The Chinese medicinal composition comprises the following raw material medicaments in part by weight: 30 to 45 parts of szechwon tangshen root, 20 to 45 parts of large-headed atractylodes rhizome, 20 to 45 parts of glossy ganoderma, 30 to 50 parts of houttuynia cordata thumb, 20 to 50 parts of weeping forsythia and 15 to 30 parts of cortex phellodendri. The Chinese medicinal composition has the effect of regulating immune cell factors, and reduces the damage of bacterial pathogens such as tumor necrosis factors, interferon-gamma blocking ureaplasma urealyticum, chlamydia trachomatis and the like to reproductive systems. In-vitro solid and liquid bacteriostatic experiments prove that the Chinese medicinal composition has the obvious bacteriostatic effect, is superior to antibiotic azithromycin applied at home and abroad, and has no toxic or side effect. The Chinese medicinal composition is mainly used for treating male and female internal and external reproductive system diseases caused by the infection of the ureaplasma urealyticum, the chlamydia trachomatis and various bacteria and virus and symptoms of infertility and the like caused by the diseases.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, relate in particular to the Chinese medicine composition of treatment ureaplasma urealyticum infection, the invention still further relates to the method for preparing of this Chinese medicine composition, belong to the Chinese medicine composition field of treating ureaplasma urealyticum infection.
Background technology
Ureaplasma urealyticum, chlamydia trachomatis infection are to influence one of healthy important pathogen in human reproduction road, and sickness rate is obvious ascendant trend in recent years, and the risk that increases the human body papillomavirus infection is arranged.Cause domestic and international stakeholder's extensive concern.At present western medical treatment is mainly used antibiotics, and along with being on the increase of Resistant strain, drug resistance constantly strengthens, weak curative effect not only, and bigger toxic and side effects is arranged, be easy to repeatedly.Market still lacks the active drug of treating this type of disease.
Summary of the invention
One of the object of the invention provides a kind of Chinese medicine composition that can effectively treat Ureaplasma urealyticum, chlamydia trachomatis infection and have the gravidity assisting effect;
Two of the object of the invention provides a kind of method for preparing above-mentioned Chinese medicine composition;
Above-mentioned purpose of the present invention realizes through following technical scheme:
A kind of Chinese medicine composition of treating ureaplasma urealyticum infection comprises that each crude drug of following weight portion is processed: Radix Codonopsis 30-45 part, Rhizoma Atractylodis Macrocephalae 20-45 part, Ganoderma 20-45 part, Herba Houttuyniae 30-50 part, Fructus Forsythiae 20-50 part and Cortex Phellodendri 15-30 part;
Preferably, the weight portion of each crude drug is: Radix Codonopsis 30-40 part, Rhizoma Atractylodis Macrocephalae 20-40 part, Ganoderma 20-40 part, Herba Houttuyniae 40-50 part, Fructus Forsythiae 30-50 part and Cortex Phellodendri 15-25 part;
Preferred, the weight portion of each crude drug is: 35 parts of Radix Codonopsis, 30 parts of the Rhizoma Atractylodis Macrocephalaes, 30 parts of Ganodermas, 45 parts of Herba Houttuyniae, 20 parts of 40 parts of Fructus Forsythiaes and Cortex Phellodendris;
The compatibility foundation of Chinese medicine composition of the present invention: Herba Houttuyniae heat-clearing and toxic substances removing in the side, eliminating carbuncle evacuation of pus.The Fructus Forsythiae heat-clearing and toxic substances removing, the eliminating carbuncle eliminating stagnation, two medicine compatibilities are monarch drug altogether.Modern pharmacological research finds that Fructus Forsythiae seed performance oil all has stronger inhibitory action to various bacteria, virus; Herba Houttuyniae has the enhancing human body immunity function simultaneously.The Cortex Phellodendri heat clearing and damp drying, skin ulcer is treated in detoxifcation, and this medicine of research proof has the obvious suppression effect to pathogenic microorganism.Radix Codonopsis, Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, building up the spleen to supplement the lung is ministerial drug.Modern study confirms that enhance immunity and the effect of regulating immunity are arranged.The Ganoderma strengthening by means of tonics, strengthening the body resistance helps the merit of Radix Codonopsis, Rhizoma Atractylodis Macrocephalae enhance immunity, helps antibacterial power such as Herba Houttuyniae, Fructus Forsythiae.Full side's compatibility gathers heat-clearing and toxic substances removing altogether, the effect of strengthening the body resistance.
The inventor passes through clinical research for many years, in conjunction with modern achievement in research, on this basis, in conjunction with the dialectical principle that combines with differential diagnosis of diseases, is the rule of treatment with strengthening the body resistance, detoxifcation thirst quenching, intends Fang Erding.
The used raw material of the present invention all can be bought from common Chinese medicine shop and obtain, and its specification meets industry standard.
Medicine activity component of the present invention can add various adjuvants required when preparing different dosage form; For example disintegrating agent, lubricant, adhesive etc.; Method of Chinese medicinal with routine is prepared into any oral formulations commonly used; Can be pill, capsule, tablet, powder, granule or oral liquid etc. for example, be preferably capsule.
Two of the object of the invention provides a kind of method for preparing above-mentioned Chinese medicine composition, comprising:
Preferably, a kind of method for preparing Chinese medicine composition of the present invention may further comprise the steps:
(1) takes by weighing each raw material by following weight portion;
(2) with the decocte with water of above Six-element crude drug, decocting liquid leaves standstill, and filters; Filtrate decompression is condensed into clear paste, spray drying, and crushing screening adds pharmaceutical preparation adjuvant preparations shaping, promptly gets.
Preferably, the decocting that above Six-element raw material is added 3-10 times of weight boils 2 times, decocts 2 hours for the first time, decocts 1.5 hours for the second time, and collecting decoction leaves standstill, and filters; Filtrate decompression is concentrated into the clear paste that relative density is 1.23-1.29 (60 ℃), spray drying, and crushing screening adds pharmaceutical preparation adjuvant preparations shaping, promptly gets.
Experimentation confirms that Chinese medicine composition of the present invention has the effect of regulating immune cell factor, through reducing the damage of bacterial pathogens such as tumor necrosis factor (TNF-α), interferon-(IFN-γ) blocking-up Ureaplasma urealyticum, chlamydia trachomatis to reproductive system.Through in-vitro solid, liquid bacteriostatic test, confirm that the fungistatic effect of Chinese medicine composition of the present invention is obvious, be superior to the antibiotic azithromycin class of present domestic and international application.And have no side effect.
Chinese medicine composition of the present invention is mainly used in the inside and outside reproductive system disease of Ureaplasma urealyticum, chlamydia trachomatis and various antibacterial, the caused men and women of viral infection, infertilities such as, repeatability miscarriage infertile like women vaginitis, cervicitis, endometritis, adnexitis, pelvic inflammatory disease, fallopian tube inflammatory and man's azoospermia, few essence, sperm deformity.
The usage of Chinese medicine composition of the present invention and consumption: the dosage of medicine of the present invention depends on concrete dosage form, and factor such as age of patient, body weight, health status.As guidance: capsule, oral, one time 2 (0.60g crude drug/grain), 3 times on the one, 7 is a course of treatment.
The specific embodiment
Further describe the present invention below in conjunction with specific embodiment, advantage of the present invention and characteristics will be more clear along with description.But these embodiment only are exemplary, scope of the present invention are not constituted any restriction.It will be understood by those skilled in the art that and down can make amendment with form or replace without departing from the spirit and scope of the present invention, but these modifications and replacing all fall in protection scope of the present invention the details of technical scheme of the present invention.
The preparation of embodiment 1 capsule
Take by weighing each raw material (unit: g): Radix Codonopsis 35, the Rhizoma Atractylodis Macrocephalae 30, Ganoderma 30, Herba Houttuyniae 45, Fructus Forsythiae 40 and Cortex Phellodendri 20 by following weight;
Above Six-element medical material adds 8 times of weight decoctings and boils 2 times, and 2 hours for the first time, 1.5 hours for the second time, collecting decoction left standstill, and filtered; Filtrate decompression is concentrated into the clear paste that relative density is 1.23-1.29 (60 ℃), and spray drying was pulverized 120 mesh sieves, adds suitable excipient,, incapsulates through granulation, dry, granulate like dextrin, starch, sucrose etc., promptly gets.
The preparation of embodiment 2 tablets
Take by weighing each raw material (unit: g): Radix Codonopsis 30, the Rhizoma Atractylodis Macrocephalae 20, Ganoderma 20, Herba Houttuyniae 30, Fructus Forsythiae 20 and Cortex Phellodendri 15 by following weight;
Above Six-element medical material adds 6 times of weight decoctings of water and boils 2 times, and 2 hours for the first time, 1.5 hours for the second time, collecting decoction left standstill, and filtered; Filtrate decompression is concentrated into the clear paste that relative density is 1.23-1.29 (60 ℃), and spray drying was pulverized 120 mesh sieves, adds suitable excipient, and through granulation, dry, granulate, tabletting, coating are processed tablet, promptly get like dextrin, starch, sucrose etc.
The preparation of embodiment 3 oral liquids
Take by weighing each raw material (unit: g): Radix Codonopsis 45, the Rhizoma Atractylodis Macrocephalae 45, Ganoderma 45, Herba Houttuyniae 50, Fructus Forsythiae 50, Cortex Phellodendri 30 by following weight;
Above Six-element medical material adds 10 times of weight decoctings and boils 2 times, and 2 hours for the first time, 1.5 hours for the second time, collecting decoction left standstill, and filtered; Add ethanol in the filtrating and make and contain the alcohol amount and reach 70-80%, left standstill 24 hours, get supernatant, add syrup after, add water to 10000ml, filter, fill, sterilization promptly gets.
The pharmacodynamics test of Test Example 1 Chinese medicine composition of the present invention
One, modeling: 6-8 week 75 of female mices of BALB/C (purchasing) in Institute of Zoology, Academia Sinica, subcutaneous injection estradiol benzoate 0.125mg, concentration 1mg/mL, continuous 4 weeks, 1 time weekly; The 2nd week of medication, vagina inoculation Ureaplasma urealyticum (UU) bacterial strain (available from Southeast China University's public medical institute microorganism and immune teaching research chamber) 50 μ L, concentration 2.5 * 105CCU/mL.After inoculating for 1 week, get vaginal secretions, UU cultivates, and culture medium becomes pink, shows the modeling success.Negative culture results person continues inoculating strain, and inoculum concentration is the same, all becomes pink until all culture medium, shows the modeling success.
Two, herbs intervention: modeling success mice is divided into model group, Chinese drug-treated group, azithromycin group at random; Every group of each 25 mice; Give normal saline, Chinese medicine (oral liquid that embodiment 3 is prepared, every milliliter contains crude drug 1.5g) respectively, azithromycin is irritated stomach, 0.4mL; Every day 1 time, intervened for 2 weeks continuously.Get vaginal secretions and do the UU cultivation.
Three, result of the test: result of the test is seen table 1.
Table 1 is respectively organized the comparison of negative conversion rate
The clinical observation on the therapeutic effect test of Test Example 2 Chinese medicine compositions of the present invention
One, clinical data
All case is from attached first hospital outpatient of December Heilongjiang University of Chinese Medicine 1 years October in 2006; Meet " sexually transmitted disease (STD) diagnostic criteria and treatment principle " (2000) nongonococcal urethritis (mucus purulence cervicitis) diagnostic criteria of national sexually transmitted disease (STD) leprosy control centre promulgation; Totally 280 examples; Be divided into Chinese drug-treated group 160 examples at random in 4: 3 ratios, Western medicine group 120 examples.
Two, diagnostic criteria
The patient has unclean property contact history or spouse to infect history; (2) cervix uteri have hyperemia, edema, touch be prone to hemorrhage, the yellow mucus purulent secretion increases and symptom such as hypogastric region discomfort; (3) secretions is cultivated the uu or the Mh positive; (4) with smear, cultivation inspection, the evidence of no NEISSERIA GONORRHOEAE and trichomonacide.
1, exclusion standard
(1) there is complication to exist; (2) there are other medicines to use history in nearly 7 days; (3) person is not made a definite diagnosis in the chamber of not experimentizing check fully; (4) fail to accomplish person's course of treatment by doctor's advice.
2, collection of specimens and detection method
Collection of specimens stops using various antibiotic and intravaginal to receive medicine in preceding 1 week.During sampling the aseptic cotton swab is stretched about 1.5-2.0cm place in people's cervix uteri mouth, be inoculated under the aseptic condition in the uu culture fluid, put in 37 ℃ of incubators and cultivate, the culture medium color person that reddens is positive behind the 24h.
Three, Therapeutic Method
The capsule that treatment group: embodiment 1 is prepared, oral, one time 2 (0.60g crude drug/grain), 3 times on the one, 7 is a course of treatment, takes medicine continuously 2 courses of treatment.
Matched group: the each 250mg of oral azithromycin serve on 7 days, two courses of treatment of continuous use every day twice.
Four, points for attention
Suitable light diet during the medication, forbidden sexual life, and forbid using together with other medicines.
Five, criterion of therapeutical effect
Recovery from illness: clinical symptom disappearance, the lab testing mycoplasma is negative.
Produce effects: clinical symptom disappearance, but lab testing uu or Mh do not turn out cloudy; Or lab testing turns out cloudy, but not complete obiteration of clinical symptoms.
Effectively: clinical symptoms partly disappears, and lab testing uu or Mh do not turn out cloudy.
Invalid: clinical symptoms is not improved, and lab testing uu or Mh do not turn out cloudy.
Six, observed result
(1) treatment group: 160 examples, cure rate 89.6%; Obvious effective rate 5.3%; Effective percentage 3.2%; Inefficiency 1.9%, total effective rate are 98.1%.
(2) azithromycin (matched group): 120 examples, cure rate 59.5%; Obvious effective rate 9.6%; Effective percentage 7.1%; Inefficiency 23.8%, total effective rate 76.2%.
Claims (8)
1. a Chinese medicine composition of treating ureaplasma urealyticum infection is processed by each crude drug of following weight portion: Radix Codonopsis 30-45 part, Rhizoma Atractylodis Macrocephalae 20-45 part, Ganoderma 20-45 part, Herba Houttuyniae 30-50 part, Fructus Forsythiae 20-50 part and Cortex Phellodendri 15-30 part.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that the weight portion of each crude drug is: Radix Codonopsis 30-40 part, Rhizoma Atractylodis Macrocephalae 20-40 part, Ganoderma 20-40 part, Herba Houttuyniae 40-50 part, Fructus Forsythiae 30-50 part, Cortex Phellodendri 15-25 part.
3. according to the described Chinese medicine composition of claim 2, it is characterized in that the weight portion of each crude drug is: 35 parts of Radix Codonopsis, 30 parts of the Rhizoma Atractylodis Macrocephalaes, 30 parts of Ganodermas, 45 parts of Herba Houttuyniae, 40 parts of Fructus Forsythiaes, 20 parts of Cortex Phellodendris.
4. according to claim 1,2 or 3 Chinese medicine composition, it is characterized in that: be prepared into oral formulations according to method of Chinese medicinal.
5. according to the Chinese medicine composition of claim 4, it is characterized in that: described oral formulations is pill, capsule, tablet, powder, granule or oral liquid.
6. method for preparing any one described Chinese medicine composition of claim 1-3 may further comprise the steps:
(1) takes by weighing each raw material by said weight portion;
(2) with the decocte with water of above Six-element crude drug, decocting liquid leaves standstill, and filters; Filtrate decompression is condensed into clear paste, spray drying, and crushing screening adds pharmaceutical preparation adjuvant preparations shaping, promptly gets.
7. according to the described method of claim 6, it is characterized in that: the decocting with 3-10 times of weight of above Six-element raw material adding in the step (2) boils 2 times, decocts 2 hours for the first time, decocts 1.5 hours for the second time, and collecting decoction leaves standstill, and filters; Relative density was the clear paste of 1.23-1.29 when filtrate decompression was concentrated into 60 ℃ of mensuration, spray drying, and crushing screening adds pharmaceutical preparation adjuvant preparations shaping, promptly gets.
8. any one described Chinese medicine composition of claim 1-3 suppresses the purposes in the medicine of ureaplasma urealyticum infection in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101695118A CN101862393B (en) | 2010-05-12 | 2010-05-12 | Chinese medicinal composition for treating ureaplasma urealyticum infection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101695118A CN101862393B (en) | 2010-05-12 | 2010-05-12 | Chinese medicinal composition for treating ureaplasma urealyticum infection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101862393A CN101862393A (en) | 2010-10-20 |
| CN101862393B true CN101862393B (en) | 2012-03-14 |
Family
ID=42954451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101695118A Expired - Fee Related CN101862393B (en) | 2010-05-12 | 2010-05-12 | Chinese medicinal composition for treating ureaplasma urealyticum infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862393B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853673A (en) * | 2016-03-05 | 2016-08-17 | 滕海斌 | Method for preventing and treating mycoplasma urealyticum infections |
| CN105726700A (en) * | 2016-03-09 | 2016-07-06 | 王磊蕾 | Method for treating mycoplasma infection |
| CN105878529A (en) * | 2016-05-20 | 2016-08-24 | 于学军 | Medicine aiming at infection after chemotherapy of lymphoma and preparation method thereof |
-
2010
- 2010-05-12 CN CN2010101695118A patent/CN101862393B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101862393A (en) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102309699A (en) | Traditional Chinese medicine (TCM) prescription for treating cervical cellulitis | |
| CN100389803C (en) | Chinese medicinal composition for treating wind-heat cold and preparation method thereof | |
| CN101862393B (en) | Chinese medicinal composition for treating ureaplasma urealyticum infection and preparation method thereof | |
| CN106309577A (en) | Antibacterial ointment for treating rhinitis and preparation method thereof | |
| CN102755559B (en) | Traditional Chinese medicine composition for treating non-gonococcal urethritis | |
| CN103463577A (en) | Agentia for treating postpartum body pain | |
| CN102526620B (en) | Traditional Chinese medicinal composition for treating gynecological inflammation and application of same | |
| CN103341059A (en) | Chinese medicine composition for treating non-gonococcal urethritis | |
| CN101884663A (en) | Traditional Chinese medicine for treating cold and parotitis | |
| CN103479737A (en) | Traditional Chinese medicine composition for treating senile cutaneous pruritus and application thereof | |
| CN101693057B (en) | Traditional Chinese medicine preparation for treating chronic pelvic inflammatory disease | |
| CN103611027B (en) | The pharmaceutical composition of a kind of clinical prevention, nursing and treatment trichomonal vaginitis | |
| CN102743686B (en) | The scorching clearing capsule of a kind of basin | |
| CN103961585A (en) | Medicament for treating postpartum nonspecific vaginitis and preparation method thereof | |
| CN102698156A (en) | Glabrous greenbrier rhizome Chinese medicinal decoction for treating edema and preparation method thereof | |
| CN102488797B (en) | Medicinal composition for treating dysmenorrhea | |
| CN101569694B (en) | Chinese medicinal preparation for treating pathogen infection of male and female urogenital system | |
| CN1306946C (en) | Snuffle dredging capsule | |
| CN103610929B (en) | Preparation method of medicament for treating chronic cervicitis | |
| CN117338844A (en) | Composition for preventing and eliminating human papilloma virus and treating cervical intraepithelial neoplasia, preparation method and application | |
| CN104857096A (en) | Traditional Chinese medicine composition for treating cervicitis | |
| CN114886993A (en) | Traditional Chinese medicine formula for treating HPV and genital tract virus infection and preparation method thereof | |
| CN102671048B (en) | Medicament for treating chronic urinary tract infections | |
| CN103989885A (en) | Traditional Chinese medicine for treating chronic pelvic inflammation | |
| CN102727742A (en) | Sealwort-ginseng particles and preparation technology thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120314 Termination date: 20150512 |
|
| EXPY | Termination of patent right or utility model |